403 related articles for article (PubMed ID: 37483515)
1. Insight into lipid-based nanoplatform-mediated drug and gene delivery in neuro-oncology and their clinical prospects.
Hegde MM; Sandbhor P; J A; Gota V; Goda JS
Front Oncol; 2023; 13():1168454. PubMed ID: 37483515
[TBL] [Abstract][Full Text] [Related]
2. Cellular and Molecular Targeted Drug Delivery in Central Nervous System Cancers: Advances in Targeting Strategies.
Zhao X; Ye Y; Ge S; Sun P; Yu P
Curr Top Med Chem; 2020; 20(30):2762-2776. PubMed ID: 32851962
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy of malignant brain tumors.
Mitchell DA; Fecci PE; Sampson JH
Immunol Rev; 2008 Apr; 222():70-100. PubMed ID: 18363995
[TBL] [Abstract][Full Text] [Related]
4. Nanoplatforms: The future of oral cancer treatment.
Senevirathna K; Jayawickrama SM; Jayasinghe YA; Prabani KIP; Akshala K; Pradeep RGGR; Damayanthi HDWT; Hettiarachchi K; Dorji T; Lucero-Prisno DE; Rajapakse RMG; Kanmodi KK; Jayasinghe RD
Health Sci Rep; 2023 Aug; 6(8):e1471. PubMed ID: 37547360
[TBL] [Abstract][Full Text] [Related]
5. Convolutions in the rendition of nose to brain therapeutics from bench to bedside: Feats & fallacies.
Goel H; Kalra V; Verma SK; Dubey SK; Tiwary AK
J Control Release; 2022 Jan; 341():782-811. PubMed ID: 34906605
[TBL] [Abstract][Full Text] [Related]
6. Translational considerations for immunotherapy clinical trials in pediatric neuro-oncology.
Foster JB; Alonso MM; Sayour E; Davidson TB; Persson ML; Dun MD; Kline C; Mueller S; Vitanza NA; van der Lugt J
Neoplasia; 2023 Aug; 42():100909. PubMed ID: 37244226
[TBL] [Abstract][Full Text] [Related]
7. On the future development of optimally-sized lipid-insoluble systemic therapies for CNS solid tumors and other neuropathologies.
Sarin H
Recent Pat CNS Drug Discov; 2010 Nov; 5(3):239-52. PubMed ID: 20722627
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic nanoplatforms and delivery strategies for neurological disorders.
Kang YJ; Cutler EG; Cho H
Nano Converg; 2018 Nov; 5(1):35. PubMed ID: 30499047
[TBL] [Abstract][Full Text] [Related]
9. Lipid nanoparticles strategies to modify pharmacokinetics of central nervous system targeting drugs: Crossing or circumventing the blood-brain barrier (BBB) to manage neurological disorders.
Correia AC; Monteiro AR; Silva R; Moreira JN; Sousa Lobo JM; Silva AC
Adv Drug Deliv Rev; 2022 Oct; 189():114485. PubMed ID: 35970274
[TBL] [Abstract][Full Text] [Related]
10. Nanoparticulate devices for brain drug delivery.
Celia C; Cosco D; Paolino D; Fresta M
Med Res Rev; 2011 Sep; 31(5):716-56. PubMed ID: 20162690
[TBL] [Abstract][Full Text] [Related]
11. The peculiar challenge of bringing CAR-T cells into the brain: Perspectives in the clinical application to the treatment of pediatric central nervous system tumors.
Del Baldo G; Del Bufalo F; Pinacchio C; Carai A; Quintarelli C; De Angelis B; Merli P; Cacchione A; Locatelli F; Mastronuzzi A
Front Immunol; 2023; 14():1142597. PubMed ID: 37025994
[TBL] [Abstract][Full Text] [Related]
12. Nanobiotechnology-based drug delivery in brain targeting.
Dinda SC; Pattnaik G
Curr Pharm Biotechnol; 2013; 14(15):1264-74. PubMed ID: 24910011
[TBL] [Abstract][Full Text] [Related]
13. Nanoparticles as immunomodulators and translational agents in brain tumors.
Grippin AJ; Dyson KA; Qdaisat S; McGuiness J; Wummer B; Mitchell DA; Mendez-Gomez HR; Sayour EJ
J Neurooncol; 2021 Jan; 151(1):29-39. PubMed ID: 32757093
[TBL] [Abstract][Full Text] [Related]
14. Recent strategies and advances in the fabrication of nano lipid carriers and their application towards brain targeting.
Agrawal M; Saraf S; Saraf S; Dubey SK; Puri A; Patel RJ; Ajazuddin ; Ravichandiran V; Murty US; Alexander A
J Control Release; 2020 May; 321():372-415. PubMed ID: 32061621
[TBL] [Abstract][Full Text] [Related]
15. Application of Therapeutic Nanoplatforms as a Potential Candidate for the Treatment of CNS Disorders: Challenges and Possibilities.
Sa P; Singh P; Dilnawaz F; Sahoo SK
Curr Pharm Des; 2022; 28(33):2742-2757. PubMed ID: 35909283
[TBL] [Abstract][Full Text] [Related]
16. TRAIL-modified, doxorubicin-embedded periodic mesoporous organosilica nanoparticles for targeted drug delivery and efficient antitumor immunotherapy.
Feng X; Li F; Zhang L; Liu W; Wang X; Zhu R; Qiao ZA; Yu B; Yu X
Acta Biomater; 2022 Apr; 143():392-405. PubMed ID: 35259519
[TBL] [Abstract][Full Text] [Related]
17. Nanomedicine-based immunotherapy for central nervous system disorders.
Hanif S; Muhammad P; Chesworth R; Rehman FU; Qian RJ; Zheng M; Shi BY
Acta Pharmacol Sin; 2020 Jul; 41(7):936-953. PubMed ID: 32467570
[TBL] [Abstract][Full Text] [Related]
18. Solid lipid nanoparticles: could they help to improve the efficacy of pharmacologic treatments for brain tumors?
Brioschi A; Zenga F; Zara GP; Gasco MR; Ducati A; Mauro A
Neurol Res; 2007 Apr; 29(3):324-30. PubMed ID: 17509234
[TBL] [Abstract][Full Text] [Related]
19. Innovative and Promising Strategies to Enhance Effectiveness of Immunotherapy for CNS Tumors: Where Are We?
Quintarelli C; Camera A; Ciccone R; Alessi I; Del Bufalo F; Carai A; Del Baldo G; Mastronuzzi A; De Angelis B
Front Immunol; 2021; 12():634031. PubMed ID: 34163465
[TBL] [Abstract][Full Text] [Related]
20. Nanoparticulate systems for drug delivery and targeting to the central nervous system.
Craparo EF; Bondì ML; Pitarresi G; Cavallaro G
CNS Neurosci Ther; 2011 Dec; 17(6):670-7. PubMed ID: 20950327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
